Outcomea | Baseline | 3-month follow-up | 6-month follow-up | 9-month follow-up | 15-month follow-up | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
ThrIVe-B | TAU | ThrIVe-B | TAU | ThrIVe-B | TAU | ThrIVe-B | TAU | ThrIVe-B–TAUb (95% CI) | ThrIVe-B | TAU | |
EQ-5D-3L | 0.52 (0.30) [− 0.18, 1] n = 20 |  | 0.65 (0.25) [0.08, 1] n = 13 | 0.59 (0.36) [− 0.18, 0.85] n = 14 | 0.51 (0.31) [− 0.02, 1] n = 14 | 0.65 (0.33) [− 0.18, 1] n = 16 | 0.63 (0.29) [0.08, 1] n = 14 | 0.63 (0.35) [− 0.08, 1] n = 17 | 0.15 (− 0.12, 0.41) n = 28 | 0.64 (0.31) [0.08, 1] n = 10 | 0.57 (0.35) [− 0.02, 1] n = 16 |
SF-36 | 0.58 (0.15) [0.26, 0.85] n = 20 | 0.64 (0.11) [0.46, 0.86] n = 20 | 0.63 (0.12) [0.39, 0.81] n = 13 | 0.63 (0.12) [0.40, 0.81] n = 17 | 0.63 (0.10) [0.50, 0.86] n = 14 | 0.64 (0.13) [0.40, 0.86] n = 17 | 0.64 (0.14) [0.37, 0.88] n = 13 | 0.60 (0.13) [0.32, 0.88] n = 16 | 0.11 (0.01, 0.20) n = 29 | 0.65 (0.12) [0.43, 0.85] n = 10 | 0.62 (0.11) [0.45 0.88] n = 15 |